Cooper Companies (NASDAQ:COO) Lowered to “Hold” Rating by Robert W. Baird

Cooper Companies (NASDAQ:COO) was downgraded by equities research analysts at Robert W. Baird from a “strong-buy” rating to a “hold” rating in a research note issued to investors on Thursday, Zacks reports.

A number of other equities analysts have also issued reports on the stock. KeyCorp restated a “sector weight” rating on shares of Cooper Companies in a research report on Friday, June 5th. Weiss Ratings reiterated a “sell (d)” rating on shares of Cooper Companies in a research report on Friday, September 4th. The Goldman Sachs Group set a $61.00 price target on shares of Cooper Companies in a research note on Wednesday, May 27th. JPMorgan Chase & Co. lowered their price objective on shares of Cooper Companies from $71.00 to $58.00 and set a “neutral” rating on the stock in a research report on Thursday. Finally, Needham & Company LLC dropped their price objective on shares of Cooper Companies from $86.00 to $73.00 and set a “buy” rating on the stock in a research note on Thursday. Five analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $71.47.

Cooper Companies Trading Down 14.7%

NASDAQ:COO opened at $54.17 on Thursday. The stock’s 50 day moving average price is $72.02 and its 200 day moving average price is $69.81. The company has a market capitalization of $10.56 billion, a PE ratio of 18.49, a P/E/G ratio of 1.66 and a beta of 0.82. The company has a quick ratio of 0.78, a current ratio of 1.27 and a debt-to-equity ratio of 0.23. Cooper Companies has a 52-week low of $51.01 and a 52-week high of $89.83.

Cooper Companies (NASDAQ:COO) last released its quarterly earnings results on Wednesday, September 9th. The medical device company reported $1.15 EPS for the quarter, topping the consensus estimate of $1.12 by $0.03. Cooper Companies had a return on equity of 10.92% and a net margin of 13.46%.The company had revenue of $1.07 billion for the quarter, compared to analyst estimates of $1.10 billion. During the same quarter in the previous year, the company posted $0.49 earnings per share. The firm’s revenue was up .5% compared to the same quarter last year. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. On average, research analysts anticipate that Cooper Companies will post 4.63 EPS for the current year.

Cooper Companies declared that its Board of Directors has authorized a stock repurchase plan on Wednesday, September 9th that authorizes the company to repurchase $3.00 billion in outstanding shares. This repurchase authorization authorizes the medical device company to purchase up to 22.7% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s management believes its stock is undervalued.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of COO. Avalon Trust Co purchased a new position in Cooper Companies in the 2nd quarter valued at $25,000. Root Financial Partners LLC raised its position in Cooper Companies by 104.5% during the 4th quarter. Root Financial Partners LLC now owns 317 shares of the medical device company’s stock worth $26,000 after buying an additional 162 shares during the last quarter. SJS Investment Consulting Inc. raised its position in Cooper Companies by 107.5% during the 1st quarter. SJS Investment Consulting Inc. now owns 361 shares of the medical device company’s stock worth $26,000 after buying an additional 187 shares during the last quarter. Elevation Wealth Partners LLC raised its position in Cooper Companies by 1,136.4% during the 2nd quarter. Elevation Wealth Partners LLC now owns 408 shares of the medical device company’s stock worth $29,000 after buying an additional 375 shares during the last quarter. Finally, Continuum Advisory LLC acquired a new stake in shares of Cooper Companies in the 2nd quarter worth $30,000. Institutional investors and hedge funds own 24.39% of the company’s stock.

Key Headlines Impacting Cooper Companies

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Cooper reported fiscal Q3 adjusted EPS of $1.15, above the $1.12 consensus estimate. The company also generated $273 million in free cash flow and repurchased $339.1 million of stock. CooperCompanies Announces Third Quarter 2026 Results
• Positive Sentiment: The board increased its share-repurchase authorization from $2 billion to $3 billion, potentially allowing repurchases of up to 22.7% of outstanding shares and signaling that management views the stock as undervalued. CooperCompanies Completes Strategic Review
• Neutral Sentiment: Analysts remain divided: Needham maintained a “buy” rating despite lowering its target to $73, while JPMorgan, UBS and Bank of America cut targets and maintained neutral ratings. The revisions imply upside from recent levels but reflect reduced estimates and greater uncertainty.
• Negative Sentiment: Revenue totaled approximately $1.066 billion, below the $1.10 billion consensus, with CooperVision revenue flat year over year. Destocking and channel-inventory reductions in the U.S. pressured contact-lens demand and overshadowed the EPS beat. COO Q3 Earnings Top Estimates
• Negative Sentiment: Cooper cut fiscal 2026 adjusted EPS guidance to $4.51–$4.55 from expectations near $4.63, and forecast fourth-quarter EPS of $1.05–$1.09 versus consensus of $1.20. Investors also reacted negatively to the decision not to pursue a sale of CooperSurgical after the strategic review. Cooper Cos. Stock Drops After Soft Outlook
• Negative Sentiment: A securities-fraud investigation announced by the Law Offices of Frank R. Cruz adds headline and legal risk, although the announcement does not establish that Cooper violated securities laws. Securities Fraud Investigation Announcement

About Cooper Companies

Cooper Companies, Inc is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company develops, manufactures and markets products through two primary business segments: CooperVision and CooperSurgical.

CooperVision specializes in contact lenses, including daily disposable, toric, multifocal, multifocal toric, specialty and myopia-management lenses. Its products are designed to address a range of vision-correction needs, including astigmatism, presbyopia and irregular corneas.